The last international consensus recommends SGLT-2 inhibitors or GLP-1 receptor agonists for patients with clinical cardiovascular disease; metformin remains the first-line therapy for glucose lowering medication [7]. This evidence concerns the gene GLP1R and cardiovascular disorder.